Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 01, 2019 16:20 ET | Source: Otonomy, Inc.

Otonomy Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Clinical-stage programs on track with results expected from three trials in 2020Current capital funds operations into 2021 Conference call and webcast today at 4:30 p.m. EDT SAN DIEGO, Aug. 01,...
July 25, 2019 16:05 ET | Source: Otonomy, Inc.

Otonomy to Report Second Quarter 2019 Financial Results and Provide Corporate Update

SAN DIEGO, July 25, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
June 12, 2019 08:00 ET | Source: Otonomy, Inc.

Otonomy to Present at the Raymond James Life Sciences and MedTech Conference

SAN DIEGO, June 12, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
May 06, 2019 16:17 ET | Source: Otonomy, Inc.

Otonomy Reports First Quarter 2019 Financial Results and Provides Corporate Update

OTO-313 Phase 1/2 trial in tinnitus initiated; results expected in first half of 2020OTIPRIO® co-promotion agreement completed with Glenmark TherapeuticsOTIVIDEX™ Phase 3 trial in Ménière’s disease on...
April 11, 2019 07:30 ET | Source: Otonomy, Inc.

Otonomy Initiates Phase 1/2 Clinical Trial of OTO-313 in Tinnitus

SAN DIEGO, April 11, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
September 24, 2015 07:30 ET | Source: Otonomy, Inc.

Otonomy to Present Results for AuriPro(TM) Phase 3 and OTO-104 Phase 2b Clinical Trials at 2015 AAO-HNSF Annual Meeting

SAN DIEGO, Sept. 24, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...